Cargando…

Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases

BACKGROUND: In the 2016 WHO classification, the diagnosis of oligodendroglioma has been restricted to IDH mutated, 1p19q codeleted tumors (IDHmut-codel). IDHmut oligoastrocytoma is now classified either as oligodendroglioma or astrocytoma based on presence of 1p19q codeletion. There is growing evide...

Descripción completa

Detalles Bibliográficos
Autores principales: Zetterling, Maria, Berhane, Luwam, Alafuzoff, Irina, Jakola, Asgeir S., Smits, Anja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706698/
https://www.ncbi.nlm.nih.gov/pubmed/29186201
http://dx.doi.org/10.1371/journal.pone.0188419
_version_ 1783282270438686720
author Zetterling, Maria
Berhane, Luwam
Alafuzoff, Irina
Jakola, Asgeir S.
Smits, Anja
author_facet Zetterling, Maria
Berhane, Luwam
Alafuzoff, Irina
Jakola, Asgeir S.
Smits, Anja
author_sort Zetterling, Maria
collection PubMed
description BACKGROUND: In the 2016 WHO classification, the diagnosis of oligodendroglioma has been restricted to IDH mutated, 1p19q codeleted tumors (IDHmut-codel). IDHmut oligoastrocytoma is now classified either as oligodendroglioma or astrocytoma based on presence of 1p19q codeletion. There is growing evidence that this molecular classification more closely reflects patient outcome. Due to the strong association between IDHmut-codel with oligodendroglial morphology, the additional impact of these markers on prognostic accuracy is largely unknown. Our aim was to assess the prognostic impact of IDHmut-codel in an unselected cohort of morphologically classified oligodendroglial tumors. METHODS: We performed a retrospective chart review of oligodendroglial tumors (WHO grade II and III) operated since 1983. A total of 214 tumors were included, and molecular information was available for 96 tumors. The prognostic impact of IDHmut-codel together with clinical parameters was analyzed by multivariate Cox regression. RESULTS: IDHmut-codel was registered in 64 tumors while for 150 tumors the molecular profile was negative for IDHmut-codel, unknown or incomplete. Comparison between the two groups showed that patients with IDHmut-codel tumors were younger (42 vs. 48 years), had more frequent frontal tumor location (48 vs. 33%) and presented more often with seizures (72 vs. 51%) and no signs of neurological impairment (14 vs. 30%) than patients harboring tumors with unknown or incomplete molecular profile. Multivariate survival analysis identified young age (HR 1.78 ≥ 40 years), the absence of neurological deficits or personality changes (HR 0.57), frontal tumor location (HR 0.64) and the presence of IDHmut-codel (HR 0.50) as independent predictors for longer survival, whereas tumor grade was not. CONCLUSION: In this unselected single-institution cohort, the presence of IDHmut-codel was associated with more beneficial clinical parameters and was identified as an independent prognostic factor. We conclude that the classical oligodendroglioma genotype provides additional prognostic data beyond clinical characteristics, morphology and tumor grade.
format Online
Article
Text
id pubmed-5706698
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-57066982017-12-08 Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases Zetterling, Maria Berhane, Luwam Alafuzoff, Irina Jakola, Asgeir S. Smits, Anja PLoS One Research Article BACKGROUND: In the 2016 WHO classification, the diagnosis of oligodendroglioma has been restricted to IDH mutated, 1p19q codeleted tumors (IDHmut-codel). IDHmut oligoastrocytoma is now classified either as oligodendroglioma or astrocytoma based on presence of 1p19q codeletion. There is growing evidence that this molecular classification more closely reflects patient outcome. Due to the strong association between IDHmut-codel with oligodendroglial morphology, the additional impact of these markers on prognostic accuracy is largely unknown. Our aim was to assess the prognostic impact of IDHmut-codel in an unselected cohort of morphologically classified oligodendroglial tumors. METHODS: We performed a retrospective chart review of oligodendroglial tumors (WHO grade II and III) operated since 1983. A total of 214 tumors were included, and molecular information was available for 96 tumors. The prognostic impact of IDHmut-codel together with clinical parameters was analyzed by multivariate Cox regression. RESULTS: IDHmut-codel was registered in 64 tumors while for 150 tumors the molecular profile was negative for IDHmut-codel, unknown or incomplete. Comparison between the two groups showed that patients with IDHmut-codel tumors were younger (42 vs. 48 years), had more frequent frontal tumor location (48 vs. 33%) and presented more often with seizures (72 vs. 51%) and no signs of neurological impairment (14 vs. 30%) than patients harboring tumors with unknown or incomplete molecular profile. Multivariate survival analysis identified young age (HR 1.78 ≥ 40 years), the absence of neurological deficits or personality changes (HR 0.57), frontal tumor location (HR 0.64) and the presence of IDHmut-codel (HR 0.50) as independent predictors for longer survival, whereas tumor grade was not. CONCLUSION: In this unselected single-institution cohort, the presence of IDHmut-codel was associated with more beneficial clinical parameters and was identified as an independent prognostic factor. We conclude that the classical oligodendroglioma genotype provides additional prognostic data beyond clinical characteristics, morphology and tumor grade. Public Library of Science 2017-11-29 /pmc/articles/PMC5706698/ /pubmed/29186201 http://dx.doi.org/10.1371/journal.pone.0188419 Text en © 2017 Zetterling et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Zetterling, Maria
Berhane, Luwam
Alafuzoff, Irina
Jakola, Asgeir S.
Smits, Anja
Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases
title Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases
title_full Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases
title_fullStr Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases
title_full_unstemmed Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases
title_short Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases
title_sort prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706698/
https://www.ncbi.nlm.nih.gov/pubmed/29186201
http://dx.doi.org/10.1371/journal.pone.0188419
work_keys_str_mv AT zetterlingmaria prognosticmarkersforsurvivalinpatientswitholigodendroglialtumorsasingleinstitutionreviewof214cases
AT berhaneluwam prognosticmarkersforsurvivalinpatientswitholigodendroglialtumorsasingleinstitutionreviewof214cases
AT alafuzoffirina prognosticmarkersforsurvivalinpatientswitholigodendroglialtumorsasingleinstitutionreviewof214cases
AT jakolaasgeirs prognosticmarkersforsurvivalinpatientswitholigodendroglialtumorsasingleinstitutionreviewof214cases
AT smitsanja prognosticmarkersforsurvivalinpatientswitholigodendroglialtumorsasingleinstitutionreviewof214cases